HiGHKOREA, a cannabis media based in Korea, reported that scientists from South Korea finished a randomized clinical trial to administer cannabidiol for pediatric patients with Lennox-Gastaut Syndrome or Dravet Syndrome. Scientists have shown CBD could reduce the seizure frequency, safe to use, and tolerable to the patients.
We analyzed 34 patients in the LGS group and 10 patients in the DS group between the ages of 1.2–15.8 years. In the 3-month evaluation, the overall reduction of seizure frequency in the LGS group was 52.9% (>50% reduction in 32.3% of the cases), and 29.4% in the 6-month evaluation (more than 50% reduction in 20.6%). In DS group, the reduction of seizure frequency by more than 50% was 30% and 20% in the 3-month and 6-month evaluation, respectively. Good outcomes were defined as the reduction of seizure frequency by more than 50% and similar results were observed in both LGS and DS groups. Adverse events were reported in 36.3% of total patients of which most common adverse events were gastrointestinal problems. However, no life-threatening adverse event was reported in both LGS and DS during the observation period. - https://doi.org/10.3346/jkms.2020.35.e427
Cannabis and cannabinoids are not evil drug, it is a vitamin which human needs.